Risperidone-associated hyperprolactinemia: Evaluation in twenty psychiatric outpatients

Pharmacological Research

Volumn 48, Issue 4, 2003, Pages 405-409

  Brunelleschi, Sandra ^a   Zeppegno, Patrizia ^a   Risso, Francesco ^a,b   Cattaneo, Carlo Ignazio ^a   Torre, Eugenio ^a  

^a UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^b ASL 15   (Italy)

Author keywords

Atypical antipsychotics; Hyperprolactinemia; Risperidone; Sexual behaviour

Indexed keywords

NEUROLEPTIC AGENT; RISPERIDONE;

ADULT; AMENORRHEA; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; GALACTORRHEA; HUMAN; HYPERPROLACTINEMIA; IMPOTENCE; INFORMED CONSENT; LIBIDO DISORDER; MALE; MENTAL PATIENT; OUTPATIENT; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PSYCHOSIS;

EID: 0041666487     PISSN: 10436618     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1043-6618(03)00174-9     Document Type: Article

References (20)

1. Halbreich U., Kinon B.J., Gilmore J.A., Kahn L.S. Elevated prolactin levels in patients with schizophrenia: mechanisms and related adverse effects. Psychoneuroendocrinology. 28:2003;53-67.
2. Kinon B.J., Gilmore J.A., Liu H., Halbreich U.M. Prevalence of hyperprolactinemia in schizophrenic patients treated with conventional antipsychotic medications or risperidone. Psychoneuroendocrinology. 28:2003;55-68.
3. Naido U., Goff D.C., Klibanski A. Hyperprolactinemia and bone mineral density: the potential impact of antipsychotic agents. Psychoneuroendocrinology. 28:2003;97-108.
4. i values. J. Pharmacol. Exp. Ther. 251:1989;238-249.
5. Remington G., Kapur S. Atypical antipsychotics: are some more atypical than others? Psychopharmacology. 148:2000;3-15.
6. Csernansky J.G., Mahmoud R., Brenner R. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N. Engl. J. Med. 346:2002;16-22.
7. Arnt J., Skarsfeldt T. Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropsychopharmacology. 18:1998;63-101.
8. 2 dopamine receptor occupancy in the living human brain. A PET study with risperidone. Psychopharmacology. 110:1993;265-272.
9. 2 receptor occupancy of clozapine. Am. J. Psychiatry. 156:1999;286-293.
10. 2 receptor occupancy in schizophrenic patients. Am. J. Psychiatry. 156:1999;869-875.
11. Bowden C.R., Voina S.J., Woestenborghs R., De Coster R., Heykants J. Stimulation by risperidone of rat prolactin secretion in vivo and cultured pituitary cells in vitro. J. Pharmacol. Exp. Ther. 262:1992;699-706.
12. Caracci G., Ananthamoorthy R. Prolactin levels in premenopausal women treated with risperidone compared with those of women treated with typical neuroleptics. J. Clin. Psychopharmacol. 19:1999;194-196.
13. Kleinberg D.L., Davis J.M., De Coster R., Van Baelen B., Brecher M. Prolactin levels and adverse events in patients treated with risperidone. J. Clin. Psychopharmacol. 19:1999;57-61.
14. Knegtering H., van der Moolen A.E., Castelein S., Kluiter H., van den Bosch R.J. What are the effects of antipsychotics on sexual dysfunction and endocrine functioning? Psychoneuroendocrinology. 28:2003;109-123.
15. Huang M.L., Van Peer A., Woestenborghs R., De Coster R., Heykants J., Jansen A.A.et al. Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects. Clin. Pharmacol. Ther. 54:1993;257-268.
16. 2 receptor occupancy induced by risperidone in poor metabolizers of debrisoquin and risperidone. Psychopharmacology. 119:1995;345-348.
17. Kapur S., Langlois X., Vinken P., Megens A.A.H.P., De Coster R., Andrews J.S. The differential effects of atypical antipsychotics on prolactin elevation are explained by their differential blood-brain disposition: a pharmacological analysis in rats. J. Pharmacol. Exp. Ther. 302:2002;1129-1134.
18. 2 receptors explain the action of atypical antipsychotics? A new hypothesis. Am. J. Psychiatry. 158:2001;360-369.
19. 2 receptor occupancy. Arch. Gen. Psychiatry. 57:2000;553-559.
20. Tauscher J., Jones C., Remington G., Zipursky R.B., Kapur S. Significant dissociation of brain and plasma kinetics with antipsychotics. Mol. Psychiatry. 7:2002;317-321.